Daisuke Arai

Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC

Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda et al. · Molecular Cancer Research · 2013 · 208 citations

Medicine, Oncology, Pharmacology +17

<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer

Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani et al. · Oncotarget · 2015 · 158 citations · Full text

Medicine, Oncology, Pharmacology +13

DOCK2 is involved in the host genetics and biology of severe COVID-19

Ho Namkoong, Ryuya Edahiro, Tomomi Takano et al. · Nature · 2022 · 97 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya et al. · European Journal of Cancer · 2021 · 89 citations

Medicine, Oncology, Pharmacology +12

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer

Masayoshi Miyawaki, Hiroyuki Yasuda, Tetsuo Tani et al. · Molecular Cancer Research · 2016 · 72 citations · Full text

Medicine, Oncology, Pharmacology +17